U.S. FDA approves Amgen's Corlanor heart failure drug

April 15, 2015 9:02 PM

9 0

(Reuters) - U.S. health regulators on Wednesday approved Amgen Inc's Corlanor to treat patients with chronic heart failure, giving the world's largest biotechnology company its first cardiovascular product.

The Food and Drug Administration approved the use of Corlanor (ivabradine) on top of current standard of care beta blockers for patients whose symptoms of heart failure are stable and who have a normal heartbeat and a resting heart rate of at least 70 beats per minute.

Also read: This Startup Is Telling Everyday Investors It Will Be The Next Uber

Read more

To category page